Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir PK and Safety in HIV-1
NCT01499199Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jan 2012
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Jan 2012; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01499199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01499199.